Table 1.
Participants becoming eligible by PLCOm2012 alone or by either PLCOm2012 or LLPv2, stratified by baseline PLCOm2012 score
| Baseline PLCOm2012 risk strata | |||||||
| 0.0–0.5 | 0.5–1.0 | 1.0–1.1 | 1.1–1.2 | 1.2–1.3 | 1.3–1.4 | 1.4–1.51 | |
| LHC attendees, n | 2993 | 1389 | 212 | 191 | 173 | 174 | 213 |
| LHC attendees becoming eligible by PLCOm2012 | 56 (1.9%) | 432 (31%) | 144 (68%) | 153 (80%) | 145 (84%) | 162 (93%) | 203 (95%) |
| Years to eligibility by PLCOm2012, median (IQR) | 14 (12–16) | 11 (8–13) | 8 (4–9) | 6 (3–7) | 4 (4–5) | 3 (2–3) | 1 (1–2) |
| Age at becoming eligible by PLCOm2012, median (IQR) | 71 (70–73) | 69 (66–72) | 68 (64–71) | 66 (63–70) | 67 (62–70) | 65 (61–69) | 63 (59–69) |
| Cancers predicted to arise before reaching eligibility by PLCOm2012 | 0.4 (0.8%) | 6.2 (1.4%) | 1.8 (1.2%) | 1.6 (1.1%) | 1.2 (0.8%) | 0.9 (0.6%) | 0.6 (0.3%) |
| LHC attendees ineligible at baseline by either PLCOm2012 or LLPv2, n | 2663 | 1133 | 159 | 137 | 117 | 110 | 140 |
| LHC attendees becoming eligible by PLCOm2012 or LLPv2 | 204 (7.7%) | 423 (37%) | 117 (74%) | 118 (86%) | 104 (89%) | 107 (97%) | 137 (98%) |
| Years to eligibility by PLCOm2012 or LLPv2, median (IQR) | 8 (5–10) | 10 (6–13) | 8 (4–9) | 6 (5–7) | 4 (4–5) | 3 (2–3) | 1 (1–2) |
| Age at becoming eligible by PLCOm2012 or LLPv2, median (IQR) | 65 (65–70) | 68 (65–71) | 67 (63–70) | 65 (62–69) | 66 (61–70) | 63 (60–69) | 61 (58–67) |
| Cancers predicted to arise before reaching eligibility by PLCOm2012 or LLPv2 | 0.5 (0.3%) | 5.4 (1.3%) | 1.4 (1.2%) | 1.3 (1.1%) | 0.9 (0.8%) | 0.6 (0.6%) | 0.4 (0.3%) |
LHC, Lung Health Check; LLPv2, Liverpool Lung Project version 2; PLCOm2012, Prostate, Lung, Colorectal and Ovarian trial’s risk model 2012.